Q2 Highlights: What We Learned at Biotrans and BIO 2025
Biocatalysis
Enzyme Engineering
Microfluidics
Synthetic Biology
Machine Learning
Protein Engineering
June 30, 2025
1min
From Basel to Boston: What We Learned at Biotrans and BIO 2025
Two global conferences. One mission: advancing enzyme innovation with speed, scale, and science.
Biotrans 2025: Where science meets application
In June, our team traveled to Basel for Biotrans 2025, a leading conference in biocatalysis. The event brought together academic researchers, startups, and industrial biotech leaders exploring the future of enzyme-enabled manufacturing.
Our CTO Dr. Akbar Vahidi and BDD Audrey L. joined the conversation and presented new case studies on how Allozymes’ platform applies microfluidics and machine learning to accelerate enzyme discovery.
“A growing number of scientists are stepping into entrepreneurship,” shared Akbar. “This shift will help scale biocatalytic solutions faster and with real-world impact.”
From pharmaceuticals to food and chemicals, the conference highlighted just how cross-cutting enzyme innovation has become.
“It was energising to reconnect with the scientific community,” Audrey added. “The coffee breaks alone were filled with ideas worth exploring.”
BIO 2025: Enzymes in the biotech spotlight
Later that month, Audrey represented Allozymes at the BIO International Convention in Boston. While broader in scope, the event reinforced a key insight — enzymes are now central to innovation in areas like NGS, gene therapy, and bioprocessing.
Our ultrahigh-throughput screening capabilities drew strong interest from biotech companies looking to improve enzyme performance while reducing development timelines.
“The pace of change is incredible,” said Audrey. “BIO was a reminder that staying connected with the global community is essential to staying ahead.”
Why it matters
These events confirmed that industries are increasingly turning to enzymes for more sustainable, precise, and scalable solutions. But traditional methods can’t keep up with the speed required.
Allozymes fills this gap with a platform designed to move faster and learn smarter.
We integrate:
- Microfluidic droplet screening that tests millions of enzyme variants per day
- AI-guided design to predict unseen combinations with high potential
- Real-time feedback loops for continuous improvement
This allows our partners to solve challenges related to activity, specificity, and stability, while dramatically shortening R&D timelines.
Let’s build better enzymes, together
If you’re exploring enzyme alternatives or looking to accelerate your development process, we’d love to collaborate.